Loss of the Tumor Suppressor HACE1 Contributes to Cancer Progression

Curr Drug Targets. 2019;20(10):1018-1028. doi: 10.2174/1389450120666190227184654.

Abstract

HACE1 belongs to the family of HECT domain-containing E3 ligases, which plays an important role in the occurrence, invasion and metastatic process in many human malignancies. HACE1 is a tumor suppressor gene that is reduced in most cancer tissues compared to adjacent normal tissue. The loss or knocking out of HACE1 leads to enhanced tumor growth, invasion, and metastasis; in contrast, the overexpression of HACE1 can inhibit the development of tumors. Hypermethylation reduces the expression of HACE1, thereby promoting tumor development. HACE1 can inhibit the development of inflammation or tumors via the ubiquitination pathway. Therefore, HACE1 may be a potential therapeutic target, providing new strategies for disease prevention and treatment.

Keywords: E3 ubiquitin protein ligase 1 (HACE1); HECT domain and ankyrin repeat containing; RAC1; methylation; tumor suppressor; ubiquitylation..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA Methylation*
  • Disease Progression
  • Down-Regulation*
  • Epigenesis, Genetic
  • Gene Expression Regulation, Neoplastic
  • Gene Knockdown Techniques
  • Humans
  • Neoplasms / genetics*
  • Ubiquitin-Protein Ligases / genetics*

Substances

  • HACE1 protein, human
  • Ubiquitin-Protein Ligases